个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Advances in developing ACE2 derivatives against SARS-CoV-2

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Haoran Zhang[1] * ; Panjing Lv[1] * ; Jingrui Jiang[1] ; Yahui Liu[1] ; Ruixi Yan[1] ; Sainan Shu[2] ; Bing Hu[4] ; Han Xiao[3] ; Kun Cai[4] ; Shuai Yuan[5,6,7,*2] ; Yan Li[1,2,*1] ;
单位： [1]Department of Pathogen Biology, School of Basic Medicine,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [2]Department of Pediatrics, Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [3]Institute of Maternal and Child Health, Wuhan Children’s Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [4]Institute of Health Inspection and Testing, Hubei Provincial Center for Disease Control and Prevention, Wuhan, China [5]State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China [6]University of Chinese Academy of Sciences, Beijing, China [7]Hubei Jiangxia Laboratory, Wuhan, China
出处：
DOI： 10.1016/S2666-5247(23)00011-3

摘要：
Extensive immune evasion of SARS-CoV-2 rendered therapeutic antibodies ineffective in the COVID-19 pandemic. Propagating SARS-CoV-2 variants are characterised by immune evasion capacity through key amino acid mutations, but can still bind human angiotensin-converting enzyme 2 (ACE2) through the spike protein and are, thus, sensitive to ACE2-mimicking decoys as inhibitors. In this Review, we examine advances in the development of ACE2 derivatives from the past 3 years, including the recombinant ACE2 proteins, ACE2-loaded extracellular vesicles, ACE2-mimicking antibodies, and peptide or mini-protein mimetics of ACE2. Several ACE2 derivatives are granted potent neutralisation efficacy against SARS-CoV-2 variants that rival or surpass endogenous antibodies by various auxiliary techniques such as chemical modification and practical recombinant design. The derivatives also represent enhanced production efficiency and improved bioavailability. In addition to these derivatives of ACE2, new effective therapeutics against SARS-CoV-2 variants are expected to be developed.Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

基金：
This study was funded by the National Key Research and Development Program of China (grant number 2021YFC2600200 and grant number 2022YFC2305500), the National Natural Science Foundation of China (grant number 82041004), and the Wuhan Institute of Virology (grant number 2022QNTJ-02).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 生物学
小类 | 1 区 微生物学 1 区 传染病学
最新[2025]版：
大类 | 1 区 生物学
小类 | 1 区 传染病学 1 区 微生物学
JCR分区：
出版当年[2021]版：
Q1 INFECTIOUS DISEASES Q1 MICROBIOLOGY
最新[2023]版：
Q1 INFECTIOUS DISEASES Q1 MICROBIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Department of Pathogen Biology, School of Basic Medicine,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Pathogen Biology, School of Basic Medicine,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [2]Department of Pediatrics, Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [5]State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China [6]University of Chinese Academy of Sciences, Beijing, China [7]Hubei Jiangxia Laboratory, Wuhan, China [*1]Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China [*2]State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
推荐引用方式(GB/T 7714)：
Haoran Zhang,Panjing Lv,Jingrui Jiang,et al.Advances in developing ACE2 derivatives against SARS-CoV-2[J].LANCET MICROBE.2023,4(5):e369-e378.doi:10.1016/S2666-5247(23)00011-3.
APA：
Haoran Zhang,Panjing Lv,Jingrui Jiang,Yahui Liu,Ruixi Yan...&Yan Li.(2023).Advances in developing ACE2 derivatives against SARS-CoV-2.LANCET MICROBE,4,(5)
MLA：
Haoran Zhang,et al."Advances in developing ACE2 derivatives against SARS-CoV-2".LANCET MICROBE 4..5(2023):e369-e378

资源点击量：434 今日访问量：0 总访问量：419 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）